Drug intelligence / Profile preview

JNJ-64457744

Development stage: Discontinued
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-64457744 is an oral small molecule drug candidate that was developed by Janssen Research & Development, a subsidiary of Johnson & Johnson. It was investigated primarily for the treatment of chronic hepatitis B (CHB), specifically in patients who are virologically suppressed on nucleos(t)ide analog treatments such as tenofovir disoproxil fumarate, tenofovir alafenamide, or entecavir. The drug underwent Phase 1 clinical trials to evaluate its safety and tolerability in both healthy volunteers and CHB patients. As of July 2023, development of JNJ-64457744 has been discontinued[1][2][4][5].

Beyond the preview

Go deeper on JNJ-64457744.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-64457744.

Explore the full profile